These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31851534)

  • 1. The effects of fasting on drug metabolism.
    Lammers LA; Achterbergh R; Mathôt RAA; Romijn JA
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):79-85. PubMed ID: 31851534
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of gut microbiota on drug metabolism and toxicity.
    Li H; He J; Jia W
    Expert Opin Drug Metab Toxicol; 2016; 12(1):31-40. PubMed ID: 26569070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population.
    Uppugunduri CR; Ansari M
    Drug Metab Lett; 2016; 10(2):72-4. PubMed ID: 26908134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota: what is its place in pharmacology?
    Tarasiuk A; Fichna J
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):921-930. PubMed ID: 31544557
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.
    Himebauch AS; Kilbaugh TJ; Zuppa AF
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1133-42. PubMed ID: 27322360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.
    Dietrich CG; Rau M; Jahn D; Geier A
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):625-640. PubMed ID: 28359183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of genetic variation in carboxylesterase drug metabolism.
    Chen F; Zhang B; Parker RB; Laizure SC
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):131-142. PubMed ID: 29264996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
    Yamazaki H
    Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
    Guengerich FP
    AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From the Viewpoint of Drug Metabolism Research].
    Nakajima M
    Yakugaku Zasshi; 2017; 137(6):697-705. PubMed ID: 28566576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenomics and the path towards personalized medicine].
    Belloso WH; Redal MA
    Medicina (B Aires); 2010; 70(3):265-74. PubMed ID: 20529779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.
    Weersink RA; Burger DM; Hayward KL; Taxis K; Drenth JPH; Borgsteede SD
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):45-57. PubMed ID: 31810397
    [No Abstract]   [Full Text] [Related]  

  • 15. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice.
    Pilotto A; Panza F; Seripa D
    Curr Drug Metab; 2011 Sep; 12(7):621-34. PubMed ID: 21495974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.
    van der Schoor LW; Verkade HJ; Kuipers F; Jonker JW
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):273-93. PubMed ID: 25380746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic implications of polymorphisms in cytochromes and drug transporters].
    Münster E; Ziegler S; Brunner M
    Wien Med Wochenschr; 2005 Feb; 155(3-4):54-8. PubMed ID: 15791777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.